[1]项三妹,李 明.参苓白术散加减治疗脾虚湿蕴型溃疡性结肠炎的疗效及对血清IL-10、PLT、Fib水平的影响[J].医学信息,2022,35(08):162-164.[doi:10.3969/j.issn.1006-1959.2022.08.042]
　XIANG San-mei,LI Ming.Efficacy of Shenlingbaizhu Powder in Treating Ulcerative Colitis with Spleen Deficiency and Damp Deposition Type and its Effect on Serum IL-10, PLT and Fib Levels[J].Medical Information,2022,35(08):162-164.[doi:10.3969/j.issn.1006-1959.2022.08.042]
点击复制

参苓白术散加减治疗脾虚湿蕴型溃疡性结肠炎的疗效及对血清IL-10、PLT、Fib水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
162-164
栏目:
中医中药
出版日期:
2022-04-15

文章信息/Info

Title:
Efficacy of Shenlingbaizhu Powder in Treating Ulcerative Colitis with Spleen Deficiency and Damp Deposition Type and its Effect on Serum IL-10, PLT and Fib Levels
文章编号:
1006-1959（2022）08-0162-03
作者:
项三妹; 李 明
（1.安徽中医药大学研究生院，安徽 合肥 230000；2.安徽中医药大学第一附属医院肛肠科，安徽 合肥 230000）
Author(s):
XIANG San-mei; LI Ming
(1.Graduate School of Anhui University of Chinese Medicine,Hefei 230000,Anhui,China;2.Department of Anorectal,the First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei 230000,Anhui,China)
关键词:
参苓白术散加减; 溃疡性结肠炎; 改良Mayo评分
Keywords:
Modified Shenlingbaizhu powder; Ulcerative colitis; Modified Mayo score
分类号:
R259；R574.62
DOI:
10.3969/j.issn.1006-1959.2022.08.042
文献标志码:
A
摘要:
目的 探讨参苓白术散加减治疗脾虚湿蕴型溃疡性结肠炎的疗效及对血清IL-10、PLT、Fib水平的影响。方法 选择2020年2月-2021年2月就诊于安徽中医药大学第一附属医院肛肠科的72例UC患者作为研究对象，按照随机数字表法分为观察组和对照组，每组36例。对照组给予美沙拉嗪肠溶片治疗，观察组在对照组基础上联合参苓白术散加减治疗，比较两组临床疗效、治疗前后中医症候得分、改良Mayo评分、IL-10、PLT、Fib水平。结果 观察组治疗总有效率为86.11%，高于对照组的69.44%（P＜0.05）；观察组治疗后中医症候得分、改良Mayo评分及IL-10、PLT、Fib水平低于对照组（P＜0.05）。结论 参苓白术散加减治疗脾虚湿蕴型溃疡性结肠炎效果确切，可降低患者血清炎性因子IL-10、PLT、Fib，改善患者临床症状，具有应用有效性。
Abstract:
Objective To explore the curative effect of Shenlingbaizhu powder in treating ulcerative colitis with spleen deficiency and damp deposition type and its effects on serum IL-10, PLT, and Fib levels.Methods A total of 72 patients with UC who were admitted to the Anorectal Department of the First Affiliated Hospital of Anhui University of Chinese Medicine from February 2020 to February 2021 were selected as the research objects. According to the random number table method, they were divided into observation group and control group, with 36 cases in each group. The control group was treated with mesalazine enteric-coated tablets, and the observation group was treated with modified Shenlingbaizhu powder on the basis of the control group. The clinical curative effect, TCM syndrome score before and after treatment, modified Mayo score, IL-10, PLT, Fib levels were compared between the two groups.Results The effective rate of treatment in the observation group was 86.11%, which was higher than 69.44% in the control group(P<0.05); after treatment, the TCM symptom score, modified Mayo score, IL-10, PLT and Fib levels in the observation group were lower than those in the control group (P<0.05).Conclusion Shenlingbaizhu powder is effective in the treatment of ulcerative colitis with spleen deficiency and damp deposition type, which can reduce the serum inflammatory factors IL-10, PLT and Fib, improve the clinical symptoms of patients, and has application effectiveness.

参考文献/References:

[1]张薇,徐婧熙,唐喜玉,等.清凉止血灌肠方联合美沙拉嗪治疗溃疡性结肠炎的回顾性分析[J].皖南医学院学报,2021,40(4):336-339.[2]蒋圣君,毛伯能.美沙拉嗪、双歧杆菌三联活菌联合复方谷氨酰胺治疗活动期轻中度溃疡性结肠炎的研究[J].河北医药,2018,40(23):3540-3544.[3]Castro-Dopico T,Dennison TW,Ferdinand JR,et al.Anti-commensal IgG drives intestinal inflammation and type 17 immunity in ulcerative colitis[J].Immunity,2019,50(4):1099-1114.[4]陈淑君,刘晓博,陈俊,等.肠清舒方治疗湿热蕴结型溃疡性结肠炎32例[J].中医研究,2021,34(8):21-24.[5]宁丽琴,叶柏,沈洪,等.国医大师徐景藩治疗溃疡性结肠炎的用药规律分析和分子靶点预测[J].中国中药杂志,2018,43(5):1042-1048.[6]吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中国实用内科杂志,2018,38(9):796-813.[7]任翔宇.益气活血汤治疗气虚血瘀型缓解期溃疡性结肠炎的临床观察[D].晋中:山西中医药大学,2019.[8]张声生,沈洪,郑凯,等.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):3585-3589.[9]温晓文,徐斌,何钦.健肠愈疡散对溃疡性结肠炎患者肠道益生菌的影响及临床疗效观察[J].中国中西医结合消化杂志,2021,29(7):479-482.[10]孔梦玉,刘晓芳,武金宝.虎地肠溶胶囊对大鼠实验性结肠炎的疗效及机制的研究[J].包头医学院学报,2021,37(3):80-85.[11]李亚,刘岩,秦燕鸿,等.健脾益气、清热化腐生肌方联合美沙拉嗪对溃疡性结肠炎患者肠黏膜屏障功能的影响[J].中国中西医结合消化杂志,2021,29(7):455-459,463.[12]沈洪,邢敬,朱磊,等.炎症性肠病中西医结合治疗策略的探索与实践[J].北京中医药,2020,39(3):191-195.[13]颜华,姜璐,曹志群.曹志群基于脏腑经络奇经理论辨治溃疡性结肠炎[J].山东中医杂志,2021,40(5):515-518.[14]李敏,刘肖.甘草泻心汤联合龙血竭胶囊治疗溃疡性结肠炎临床研究[J].河南中医,2021,41(6):840-843.[15]张雯婷,顾林,柯希权,等.溃疡性结肠炎患者中TLR9和STAT3的表达及其与IL-10的相关性研究[J].中华全科医学,2021,19(6):921-924.[16]Chen YY,Ma ZB,Xu HY,et al.IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis[J].Int J Clin Exp Med,2015,8(8):12009-12017.[17]褚胜苹.D-二聚体、PT、FIB、PLT在溃疡性结肠炎中临床意义的探讨[D].大连:大连医科大学,2015.[18]赵文娟,侯新.参苓白术散联合美沙拉秦肠溶片治疗脾虚湿阻型溃疡性结肠炎临床观察[J].中医临床研究,2020,12(19):78-80.[19]梁想,王梅青.参苓白术散联合美沙拉嗪治疗溃疡性结肠炎疗效研究[J].陕西中医,2020,41(9):1251-1253.

相似文献/References:

[1]杜丽君.穴位埋线疗法联合口服美沙拉嗪治疗溃疡性结肠炎的 护理分析[J].医学信息,2018,31(05):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
　DU Li-jun.Nursing Analysis of Acupoint Catgut Embedding Therapy Combined with Oral Mesalazine in the Treatment of Ulcerative Colitis[J].Medical Information,2018,31(08):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
[2]张君红,李洪梅,井 洁,等.溃疡性结肠炎中西医结合治疗研究[J].医学信息,2018,31(09):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
　ZHANG Jun-hong,LI Hong-mei,JING Jie,et al.Study on the Treatment of Ulcerative Colitis with Integrated Traditional Chinese and Western Medicine[J].Medical Information,2018,31(08):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
[3]李 伟,徐 伟.溃疡性结肠炎中医干预治疗研究[J].医学信息,2022,35(09):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
　LI Wei,XU Wei.Study on Traditional Chinese Medicine Intervention Treatment of Ulcerative Colitis[J].Medical Information,2022,35(08):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
[4]汤胜男,赵党生,王凤仪,等.芍药汤治疗溃疡性结肠炎的研究[J].医学信息,2019,32(15):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
　TANG Sheng-nan,ZHAO Dang-sheng,WANG Feng-yi,et al.Study on Treating Ulcerative Colitis with Shaoyao Decoction[J].Medical Information,2019,32(08):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
[5]宋 崟,张 科.基于生物信息学方法探究溃疡性结肠炎的关键基因和通路[J].医学信息,2022,35(16):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
　SONG Yin,ZHANG Ke.Key Genes and Pathways of Ulcerative Colitis Based on Bioinformatics[J].Medical Information,2022,35(08):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
[6]华 琳,陈元旺,唐 静,等.溃疡性结肠炎患者外周血Tim-4 mRNA表达水平的变化及意义[J].医学信息,2019,32(21):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
　HUA Lin,CHEN Yuan-wang,TANG Jing,et al.Changes and Significance of Tim-4 mRNA Expression in Peripheral Blood of Patients with Ulcerative Colitis[J].Medical Information,2019,32(08):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
[7]徐 杰.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果比较[J].医学信息,2020,33(04):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
　XU Jie.Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis[J].Medical Information,2020,33(08):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
[8]牙韩清,郑琴芳,何志钧.溃疡性结肠炎相关结直肠癌手术治疗现况[J].医学信息,2020,33(07):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
　YA Han-qing,ZHENG Qin-fang,HE Zhi-jun.Surgical Treatment of Ulcerative Colitis-related Colorectal Cancer[J].Medical Information,2020,33(08):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
[9]王莹洁,戴迟兵.益生菌在炎症性肠病中的应用研究[J].医学信息,2020,33(22):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
　WANG Ying-jie,DAI Chi-bing.Study on the Application of Probiotics in Inflammatory Bowel Disease[J].Medical Information,2020,33(08):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
[10]朱 燕,刘大铭,刘全喜,等.溃疡性结肠炎中医诊疗思路[J].医学信息,2021,34(03):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]
　ZHU Yan,LIU Da-ming,LIU Quan-xi,et al.TCM Diagnosis and Treatment of Ulcerative Colitis[J].Medical Information,2021,34(08):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]

更新日期/Last Update: 1900-01-01